34 results about "Hepatorenal syndrome" patented technology

The invention discloses a traditional Chinese medicine composition for treating acute hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicinal herbs: radix bupleuri, folium isatidis, isatis root, chrysanthemum, taraxacum officinale root, herba violae, pericarpium citri reticulatae viride, rhizoma cyperi, costus root, hawthorn, angelica sinensis, raw rehmannia, radix scrophulariae, root of kudzu vine, radix paeoniae alba, soapstone, cape jasmine, houttuynia cordata, subprostrate sophorae, rhizoma smilacis glabrae, oriental wormwood, indigo naturalis, coptis, rheum officinale, felwort, ash bark, radix sophorae falvescentis, bunge cherry seed, lophatherum gracile, bezoar, antelope's horn, patrinia, lithospermum, moutan bark and root of common peony. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of inappetence, hepatitis B virus, hepatitis B carrier, arcane positive, greasy antiposia, diarrhea, jaundice, hepatic encephalopathy, electrolyte disturbance, encephaledema, cerebral hernia, hepatorenal syndrome, hydroperitoneum, electrolyte disturbance and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible Chinese medicinal herbs specified in National Formulary, the traditional Chinese medicine composition has the advantages of low cost, basic no toxic and side effects, and the like.

In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and/or HRS and/or other kidney diseases in cirrhosis subjects. In another embodiment, the present invention is directed to prognostic methods for predicting disease-specific mortality in cirrhosis patients. In some aspects, the diagnostic and prognostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range.

A method of treating a patient with cardiorenal syndrome and hepatorenal syndrome are provided in which a portion of the body fluid of the patient is exposed to renal epithelial cells, outside of the kidney of the patient, whereby the body fluid is in fluid communication with renal epithelial cells and is modified by renal epithelial cells.

The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A₂ receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A₂ receptor antagonist to a patient in need thereof.

The invention relates to a traditional Chinese medicine for treating hepatorenal syndrome. The traditional Chinese medicine is prepared from the following medical materials in weight ratio: 12 parts of rhizoma curcumae longae, 6 parts of gynostemma pentaphylla, 8 parts of radix scrophulariae, 8 parts of apocynum venetum, 4 parts of lumbricus, 4 parts of saffron crocus, 7 parts of saussurea involucrate, 7 parts of Chinese lobelia, 7 parts of Szechuan lovage rhizome, 12 parts of radix polygonati officinalis, 12 parts of polygonum multiflorum, 6 parts of eucommia ulmoides and 8 parts of gecko. Clinical trials prove that the traditional Chinese medicine can be used for treating hepatorenal syndrome safely and effectively.

The invention discloses a system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients. The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients includes an input device, a computing device and an output device, wherein the computing device includes a memory and a processor; a computer program is saved in the memory;the processor is configured to execute the computer program saved in the memory so as to realize the algorithm of a discrimination function; and the discrimination function returns the short-term prognosis of hepatorenal syndrome patients to be tested through liver cancer history, creatinine (Cr), neutrophilic granulocyte percentage (NE%) and glutamic-pyruvic transaminase (ALT). The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients performs analysis and comparison by means of the current easily obtained clinic lab test index, establishes a survival prognosis scoring model for hepatic cirrhosis and hepatorenal syndrome patients, and guides the patients to further complete the related treatment to prolong the survival time of the patients.

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicinal composition for treating essence-blood deficiency type hepatorenal syndromes. The traditional Chinese medicinal composition comprises, by weight, 4-8 parts of Colla Corii Asini, 4-8 parts of Radix Crepis Rigescentis, 4-8 parts of black sesame, 4-8 parts of Radix Cynanchi Bungei, 4-8 parts of root of shrubbery rhodiola, 4-8 parts of Rubus Hirsutus, 4-8 parts of Gymnadenia Conopsea, 4-8 parts of Elatostema Myrtillus and 4-8 parts of glycyrrhiza. The traditional Chinese medicinal composition has the advantages that the effect of tonifying essence, enriching blood and nourishing liver and kidney is achieved through combination of the herbs; clinical symptoms and signs of patients can be relieved effectively, the levels of blood urea nitrogen, creatinine and urine protein can be reduced, glomerular filtration rate can be increased, and renal function can be improved; the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase can be reduced, and liver function can be improved.

The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating hepatorenal syndrome of water-damp internal stop type. The traditional Chinese medicine composition is composed of the following traditional Chinese medicines in parts by weight: 4-8 parts of golden cocktail, 4-8 parts of Dahonghuadiandimei, 4-8 parts of red chopsticks, 4-8 parts of ground pepper, 4-8 parts of milk ginseng 4-8 parts of black sesame, 4-8 parts of licorice. The combined use of all medicines has the effects of diuresis and dampness, invigorating the spleen and promoting qi, and nourishing the liver and kidney. It can effectively improve the clinical symptoms and signs of patients, reduce blood urea nitrogen, creatinine, and urine protein levels, increase glomerular filtration rate, improve renal function, and at the same time reduce the levels of alanine aminotransferase and aspartate aminotransferase, and improve liver function.

The invention discloses a Chinese medicinal preparation for curing hepatorenal syndrome, which comprises the following selected raw material medicaments in part by weight: 15 parts of rhizoma corydalis, 15 parts of kudzu-vine root, 15 parts of goldthread root, 15 parts of Chinese angelica, 15 parts of exocarpium citri leiocarpae, 15 parts of peach seed, 15 parts of incised notopterygium rhizome, 10 parts of pilose asiabell root, 10 parts of stir-fried bitter orange, 10 parts of eupolyphaga, 10 parts of largeleaf gentian root and 6 parts of liquoric root. The preparation formulations comprise pills, powder, tablets, oral liquid and capsules which are prepared by the conventional preparation process or the modern preparation process. After being used together, the selected medicinal materials have the effects of replenishing qi and tonifying middle-Jiao, dissipating blood stasis with potent drugs, inducing perspiration and relieving muscles, clearing away heat and promoting eruption, inviting body fluid and pacifying thirst and lifting yang and relieving diarrhea. By oral administration, the Chinese medicinal preparation improves immune function of the organism, has good curative effect on the hepatorenal syndrome caused by various causes of disease and has convenient administration. Clinical application shows that the Chinese medicinal preparation has the advantages of rapid response, obvious curative effect, good tolerance, low cost and no any toxic or side effect.

The invention discloses a traditional Chinese medicine prescription for treating hepatorenal syndrome and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine prescription is used for treating hepatorenal syndrome. The traditional Chinese medicine prescription comprises the following raw materials in parts by weight: 3-6 parts of codonopsis pilosula, 2-4 parts of almond, 5-10 parts of fried eucommia ulmoides, 3-6 parts of root of kudzu vine, 3-6 parts of poria cocos, 2-4 parts of fried fructus aurantii, 2-4 parts of pinellia ternate, 1-3 parts of semen cassia, 2-4 parts of musk, 2-4 parts of liquorice, 1-3 parts of Cape jasmine, 2-3 parts of barley, 1-3 parts of platycodon grandiflorum, 2-4 parts of astragalus membranaceus, 1-3 parts of semen coicis, 2-4 parts of Chinese yam, 2-3 parts of Chinese lobelia, 1-2 parts of large-leaved gentian, 1-2 parts of panax notoginseng, 1-4 parts of radix bupleuri, 2-3 parts of asarum and 5-8 parts of the fruit of Chinese wolfberry. According to the traditional Chinese medicine prescription, the liver decompensation of the hepatorenal syndrome can be effectively relieved, a functional renal failure can be treated, and the blood urea nitrogen level and the probability of caused complications can be lowered.

The invention discloses application of a CTSG (cathepsin G) cell factor in the preparation of medicaments to treat hepatic failure. Death of mass hepatic cells occurs during the course of hepatic failure; the CTSG cell factor helps overcome the aforementioned problem. CTSG JNK (c-Jun N-terminal kinase) is one of MAPK (mitogen-activated protein kinase) family members; JNK pathway can inhibit apoptosis of hepatic cells by regulating the expression of CTSG. The CTSG cell factor can be applied to the preparation of medicaments to treat hepatic failure to significantly increase biochemical indexesof a patient, reduce bilirubin level, lower aminotransferase, improve the coagulation function, inhibit cell apoptosis, promote the regeneration of hepatic cells and bile duct cells, prevent occurrence of fatal complications, such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome, extend the survival time of the patient significantly, and increase the survival rate.

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Troxerutin and significant parts of herba erigerontis flavones are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating cerebral thrombus, cerebral infarction, cerebral hemorrhage, senile dementia, angina pectoris caused by coronary disease, myocardial infarction, auricular fibrillation, viral myocarditis, pulmonary heart disease, retina venous clogging, thrombotic phlebitis, capillary vessel hemorrhage, hepatorenal syndrome, diabetes and complications. The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved curative effect, wider range of safely, and less fluctuation of treatment effects.

The invention discloses application of a VSIG4 cytokine in preparation of a medicament for treating hepatic failure. The dose form of the medicament is an injection or a lyophilized powder injection or a suspension, the application temperature of the VSIG4 cytokine-containing medicament is 15-30 DEG C, and the humidity is 45-75%. The VSIG4 is a member of an ABCA superfamily and is mainly used formediating transmembrane transport of lipids and regulating metabolic disorders such as hepatocyte steatosis during hepatic failure. In the application of the VSIG4 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the blood coagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding,severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.

The invention relates to the technical field of a pure traditional Chinese medicine, in particular to a medicine for treating ascites due to cirrhosis and hepatorenal syndrome, and a preparation method thereof. The medicine overcomes different defects respectively existing in medicines and methods for treating kidney diseases and uremia. The medicine of the invention is prepared by musk, red ginseng, barley, cornu saigae tataricae, radix asparagi, tuber pinellia, Chinese yam, tuckahoe, liquorice, ballonflower and honeysuckle. The preparation method comprises the following steps: the medicines are respectively pulverized; the liquorice, the ballonflower and the honeysuckle are mixed, and water is added in the mixture; after being boiled by hard fire, the mixture is decocted by soft fire; after the mixture is placed for 24 hours, water, the weight of which is equal to that of the water added in the first time is added; then, the mixture is decocted by soft fire after being boiled by hard fire; the steps are repeated seven times according to the method; the obtained medical liquor is filtered, and other powdery medicines are added in the filter liquor; the mixture is uniformly stirred and kneaded to obtain tablets, and the tablets are dried. The medicine of the invention plays a role of treating both manifestation and root cause of disease, combining tonification and purgation, tonifying the kidney and yang, replenishing qi and blood, expelling toxin, promoting urination and protecting the kidney, and has reliable and safe curative effect. In addition, the medicine has good functions of reducing albuminuria and erythruria, metabolizing the kidney and expelling toxin.

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating a Qi-stagnation and blood stasis type hepatorenal syndrome. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of whitewood, 4-8 parts of Sterculia nobilis shells, 4-8 parts of the seeds of Lathyrus davidii, 4-8 parts of the fruits of Manglietia yuyuanensis, 4-8 parts of dysosma versipellis, 4-8 parts of the root of Undulateleaf Aralia, 4-8 parts of Akebia trifoliate, 4-8 parts of Orchidaceae Pecteilis, 4-8 parts of phoenix hawksbeard roots, 4-8 parts of semen sesami nigrum and 4-8 parts of licorice roots. All the medicinal materials are combined to achieve the effects of soothing the liver, promoting the circulation of qi, promoting blood circulation to remove blood stasis and tonifying the liver and kidney. The clinical symptoms and physical signs of the patient can be effectively relieved, the level of blood urea nitrogen, creatinine and urine protein can be lowered, the glomerular filtration rate can be improved, the kidney function can be improved, the glutamic-pyruvic transaminase and glutamic oxalacetic transaminase level can be lowered, and the liver function can be improved.

The invention discloses application of a PRRT4 (proline rich transmembrane protein 4) cell factor in the preparation of drugs to treat hepatic failure. The drugs include PRRT4 cell factor pharmaceutically-acceptable excipients, antioxidants and vectors. The course of hepatic failure is involved with severe metabolic disorders, especially lipidosis. PRRT4 cell factor can overcome the difficulty; PRRT4 is associated with the functionality of mesenchymal stem cells and can promote the treatment of liver healing. In the application in the preparation of drugs to treat hepatic failure, PRRT4 cell factor can evidently increase biochemical indexes of a patient, lower bilirubin level, reduce aminotransferase, improve the coagulation function, increase the albumin level, inhibit apoptosis of hepatic cells, promote the regeneration of hepatic cells and bile tube cells, prevent fatal complications, such as upper gastrointestinal bleeding, severe hepatic encephalopathy and hepatorenal syndrome, evidently extend the survival time, and increase the survival rate.

The invention discloses an application of an ABCA13 cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the ABCA13 cytokine, and the drug is in the form of an injection, a freeze-dried powder injection or a suspension. ABCA13 is one of ABCA superfamily members, mediates transmembrane transport of lipids and adjusts metabolic disorders such as hepatocyte steatosis and the like in the hepatic failure process, and ABCA13 is functionally related with mesenchymal stem cells and has a treatment effect for promoting liver repair. According to the application of the ABCA13 cytokine to preparation of the hepatic failure treatment drug, biochemical indexes of a patient can be remarkably improved, bilirubin level and transaminase are reduced, coagulation function and albumin level are improved, fatal complications such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome are prevented, the survival time is remarkably prolonged, and the survival rate is increased.

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for treating hepatorenal syndrome due to blood stasis causing water retention. The composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 4-8 parts of black soybeans, 4-8 parts of lysimachia barystachys bunge, 4-8 parts of aralia undulata, 4-8 parts of blumea balsamifera root, 4-8 parts of broad bean shells, 4-8 parts of shells of sterculia nobilis smith, 4-8 parts of rhodiola dumulosa, 4-8 parts of fruits of rubus hirsutus thunb and 4-8 parts of licorice root. The medicinal materials are combined to achieve the effects of promoting blood circulation, inducing diuresis, tonifying kidneys and nourishing liver. The traditional Chinese medicine composition can be used for effectively improving the clinical symptoms and signs of patients, reducing the level of blood urea nitrogen, creatinine and urine protein, improving the glomerular filtration rate, improving the renal functions, reducing the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase and improving liver functions.